Bristol-Myers-Squibb (BMY) says the US FDA has accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
#BRISTOL-MYERS SQUIBB CO#BMY.US#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#BMY#US EQUITIES